Skip to main content
SpringerLink
Log in

Taurine Improves the Actions of Metformin and Lovastatin on Plasma Markers of Carbohydrate and Lipid Dysfunction of Diabetic Rats

  • Conference paper
  • First Online:
Taurine 11

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1155))

Abstract

The present study has investigated the effect of adding taurine (TAU) to a treatment of diabetes with metformin (MET), a hypoglycemic, and lovastatin (LOV), an antihyperlipidemic. To this end, male Sprague-Dawley rats, agent, 250–275 g in weight, were made diabetic with a single 60 mg/kg intraperitoneal (i.p.) dose of streptozocin (STZ) in 10 mM citrate buffer pH 4.5, and, after 14 days, treated daily with oral doses of MET (2.4 mM/kg), LOV (0.075 mM/kg) or TAU (2.4 mM/kg), and with binary and ternary combinations of these agents. Rats receiving only 10 mM citrate buffer pH 4.5 or only STZ served as negative and positive controls, respectively. In addition, rats receiving insulin (INS, 4 units/kg) by the subcutaneous route served as a reference treatment. All the rats were sacrificed on day 57 and their bloods collected into heparinized tubes. The corresponding plasma samples were analyzed for their glucose (GLC), insulin (INS), glycated hemoglobin (HbA1c), cholesterol (CHOL) and triglycerides (TG) contents. In comparison to normal rats, diabetic ones showed marked increases in GLC (+313%), HbA1c (+207%), CHOL (+66%) and TG (+188) and a profound decrease of INS levels (−76%) (p < 0.001 vs. control values). Among the various treatments, one with INS produced the greatest lowering effect on the plasm a GLC (+23%, p < 0.05), INS (+23%, p < 0.05) and TG (+3%), with the remaining changes being similar to those seen with MET. A treatment with MET reduced all the diabetic changes by at least threefold; and one with LOV had a significant (p < 0.001) lowering effect on the plasma CHOL and TG but was without an effect on the plasma GLC, INS and HbA1c. In common with LOV, TAU reduced the diabetic levels of both CHOL and TG and, in addition, reduced the diabetic plasma GLC and raised the corresponding INS level. Among binary combinations, one with LOV-MET provided a greater effect than MET alone only in terms of the plasma CHOL and TG; and one with LOV-TAU was only significantly better than TAU alone in lowering the TG levels. However, a treatment with LOV-MET-TAU led to reductions in all the plasma parameters examined that were much greater than those achieved with any of the individual agents or with their binary combinations (at p ≤ 0.05).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 329.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 419.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CHOL:

Cholesterol

DM:

Diabetes mellitus

GLC:

Glucose

HbA1c:

Glycated hemoglobin

INS:

Insulin

LOV:

Lovastatin

MET:

Metformin

STZ:

Streptozotocin

TAU:

Taurine

TG:

Triglycerides

References

  • Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475

    CAS  PubMed  Google Scholar 

  • Alvarado-Vásquez N, Zamudio P, Cerón E, Vanda B, Zenteno E, Carvajal- Sandoval G (2003) Effect of glycine in streptozotocin-induced diabetic rats. Comp Biochem Physiol Part C Toxicol Pharmacol 134:521–527

    Article  Google Scholar 

  • Bailey CJ, Mynett KJ, Page T (1994) Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 112:671–675

    Article  CAS  Google Scholar 

  • Brøns C, Spohr C, Storgaard H, Dyerberg J, Vaag A (2004) Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur J Clin Nutr 58:1239–1247

    Article  Google Scholar 

  • Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 50:385–432

    Article  CAS  Google Scholar 

  • Carlsen SM, Rossvoll O, Bjerve KS, Folling I (1996) Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 239:227–233

    Article  CAS  Google Scholar 

  • Carneiro EM, Latorraca MQ, Araujo E, Beltrá M, Oliveras MJ, Navarro M, Berná G, Bedoya FJ, Velloso LA, Soria B, Martín F (2009) Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochem 20:503–511. 2009

    Article  CAS  Google Scholar 

  • Chogtu B, Magazine R, Bairy KL (2015) Statin use and risk of diabetes mellitus. World J Diabetes 6:352–357

    Article  Google Scholar 

  • Garg A, Grundy SM (1988) Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 318:81–86

    Article  CAS  Google Scholar 

  • Guo J, Gao Y, Cao X, Zhang J, Chen W (2017) Cholesterol-lowering effect of taurine in HepG2 cell. Lipids Health Dis 16:56

    Article  Google Scholar 

  • Hother-Nielsen O, Schmitz O, Andsersen PH, Beck-Nielsen H, Pedersen O (1989) Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 120:257–265

    Article  CAS  Google Scholar 

  • Ito T, Schaffer SW, Azuma J (2012) The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 42:1529–1539

    Article  CAS  Google Scholar 

  • Kim KS, Oh DH, Kim JY, Lee BG, You JS, Chang KJ, Chung HJ, Yoo MC, Yang HJ, Kang JH et al (2012) Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. Exp Mol Med 44:665–673

    Article  CAS  Google Scholar 

  • Koh JH, Lee ES, Hyun M, Kim HM, Choi YJ, Lee EY, Yaday D, Chung CH (2014) Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model. Int J Endocrinol 2014:397307

    Article  Google Scholar 

  • Kulakowski EC, Maturo J (1984) Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem Pharmacol 33:2835–2838

    Article  CAS  Google Scholar 

  • Luippold G, Bedenik J, Voigt A, Grempler R (2016) Short- and longterm glycemic control of streptozotocin-induced diabetic rats using different insulin preparations. PLoS One 11:e0156346

    Article  Google Scholar 

  • Mikami N, Hosokawa M, Miyashita K (2012) Dietary combination of fish oil and taurine decreases fat accumulation and ameliorates blood glucose levels in type 2 KK-Ay mice. J Food Sci 77:H114–H120

    Article  CAS  Google Scholar 

  • Murakami S, Fujita M, Nakamura M, Sakono M, Nishizono S, Sato M, Imaizumi K, Mori M, Fujuda N (2016) Taurine ameliorates cholesterol metabolism by stimulating bile acid production in high-cholesterol-fed rats. Clin Exp Pharmacol Physiol 43:372–378

    Article  CAS  Google Scholar 

  • Nishimura N, Umeda C, Oda H, Yokogoshi H (2002) The effect of taurine on plasma cholesterol concentration in genetic type 2 diabetic GK rats. J Nutr Sci Vitaminol 48:483–490

    Article  CAS  Google Scholar 

  • Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607–614

    Article  CAS  Google Scholar 

  • Pandya KG, Budhram R, Clark GJ, Lau-Cam CA (2015) Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function. Adv Exp Med Biol 803:227–250

    Article  CAS  Google Scholar 

  • Periello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB (1994) Acute anti-hyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920–928

    Article  Google Scholar 

  • Pournaghi P, Sadrkhanlou RA, Hasanzadeh S, Foroughi A (2012) An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats. Vet Res Forum 3:79–84

    PubMed  PubMed Central  Google Scholar 

  • Raabo E, Terkildsen TC (1960) On the enzymatic determination of blood glucose. Scand J Clin Invest 12:402–407

    Article  CAS  Google Scholar 

  • Rena G, Hardie DG, Pearso ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577–1585

    Article  CAS  Google Scholar 

  • Ribeiro RA, Bonfleur ML, Amaral AG, Vanzela EC, Rocco SA, Boschero AC, Carneiro EM (2009) Taurine supplementation enhances nutrient-induced insulin secretion in pancreatic mice islets. Diabetes Metab Res Rev 25:370–379

    Article  CAS  Google Scholar 

  • Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS (1998) The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 21:701–705

    Article  CAS  Google Scholar 

  • Saleh AA (2012) Effects of taurine and/or ginseng and their mixture on lipid profile and some parameters indicative of myocardial status in streptozotocin-diabetic rats. J Basic Appl Zool 65:267–273

    Article  CAS  Google Scholar 

  • Stowe NT, Cressman MD, Brouhard BH, Nally JV Jr, Vidt DG, Inman SR, Satoh S, Satodate R (1999) Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317:215–221

    Article  Google Scholar 

  • Tenner TE Jr, Zhang XJ, Lombardini JB (2003) Hypoglycemic effects of taurine in the alloxan-treated rabbit, a model for type 1 diabetes. Adv Exp Med Biol 526:97–104

    Article  CAS  Google Scholar 

  • Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 107:387–392

    Article  CAS  Google Scholar 

  • Tobin BW, Welch-Holland KR, Marchello MJ (2000) Increased body fat in streptozotocin diabetic rats treated with intensive subcutaneous insulin therapy vs. islet transplantation. Can J Physiol Pharmacol 78:622–630

    Article  CAS  Google Scholar 

  • Tokunaga Y, Yoneda Y, Kuriyama K (1983) Streptozotocin-induced elevation of a pancreatic taurine content and suppressive effect of taurine on insulin secretion. Eur J Pharmacol 87:237–243

    Article  CAS  Google Scholar 

  • Tsuchiya Y, Kawamata K (2017) Effects of taurine on plasma glucose concentration and active glucose transport in the small intestine. Anim Sci J 88:1763–1767

    Article  CAS  Google Scholar 

  • Vergés B (2015) Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 58:886–899

    Article  Google Scholar 

  • Wang L, Zhang L, Yu Y, Wang Y, Niu N (2008) The protective effects of taurine against early renal injury in STZ-induced diabetic rats, correlated with inhibition of renal LOX-1-mediated ICAM-1 expression. Ren Fail 30:763–671

    Article  CAS  Google Scholar 

  • Yanagita T, Han S-Y, Hu Y, Nagao K, Kitajima H, Murakami S (2008) Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 7:38

    Article  Google Scholar 

  • Yokogoshi H, Mochizuki H, Nanami K, Hida Y, Miyachi F, Oda H (1999) Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr 129:1705–1712

    Article  CAS  Google Scholar 

  • Zhang M, Bi LF, Fang JH, Su XL, Da GL, Kuwamori T, Kagamimori S (2004) Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids 26:267–271

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Professions, St. John’s University, Jamaica, NY, USA

    Kashyap Pandya & Cesar A. Lau-Cam

Authors
  1. Kashyap Pandya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cesar A. Lau-Cam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Shenyang, Liaoning, China

    Jianmin Hu

  2. Department of Occupational and Environmental Health, Dalian Medicine University, Dalian, Liaoning, China

    Fengyuan Piao

  3. Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, USA

    Stephen W. Schaffer

  4. Department of Biology, Center for Developmental Neuroscience, College of Staten Island, Staten Island, NY, USA

    Abdeslem El Idrissi

  5. Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA

    Jang-Yen Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Pandya, K., Lau-Cam, C.A. (2019). Taurine Improves the Actions of Metformin and Lovastatin on Plasma Markers of Carbohydrate and Lipid Dysfunction of Diabetic Rats. In: Hu, J., Piao, F., Schaffer, S., El Idrissi, A., Wu, JY. (eds) Taurine 11. Advances in Experimental Medicine and Biology, vol 1155. Springer, Singapore. https://doi.org/10.1007/978-981-13-8023-5_8

Download citation

Publish with us

Policies and ethics

Search

Navigation